Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
The data presents 75 chronic myeloid leukemia patients diagnosed over a period 6 years i.e. from 2002 to 2008. The most common presentation was splenomegaly and 97% achieved complete hematological response at median duration of 4.3 weeks. The uniqueness of this study is follow-up with molecular resp...
Saved in:
| Main Authors: | D C Doval, Ullas Batra, Sumit Goyal, Ajay Sharma, Saud Azam, Rashmi Shirali |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2013-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=3;spage=182;epage=185;aulast=Doval |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01) -
Profile of pediatric chronic myeloid leukemia in the era of imatinib: A study from South India
by: Catherene Bernard, et al.
Published: (2019-01-01) -
Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
by: L. A. Antipova, et al.
Published: (2022-11-01) -
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01) -
BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)